The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1533
November 6, 2017
View Complete Issue         Table of Contents 2019 
Edaravone (Radicava) for ALS
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Edaravone (Radicava) for ALS
November 6, 2017 (Issue: 1533)
The FDA has approved edaravone (Radicava – Mitsubishi Tanabe Pharma) for treatment of amyotrophic lateral sclerosis (ALS). It is the second drug to be approved in the US for this indication; riluzole (Rilutek, and generics) was approved in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Edaravone (Radicava) for ALS
Article code: 1533b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.